Kura Oncology To Host Dec. 8 Virtual Investor Event On Triplet Therapy Data For AML Ahead Of ASH 2025

Kura Oncology, Inc. (NASDAQ:KURA), a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that it will be hosting a virtual analyst and investor event on Monday, December 8, 2025, at 12:30 PM ET / 9:30 AM PT, to discuss data on the triplet combination of ziftomenib (KOMZIFTI®) with venetoclax and azacitidine in newly diagnosed and relapsed/refractory acute myeloid leukemia scheduled for presentation at the 67th American Society of Hematology (ASH) Annual Meeting.

The virtual event will feature members of the management team alongside lead investigators. The live webcast and replay will be available on the Company's website at www.kuraoncology.com under the Investors tab in the Events and Presentations section.